Calumet is rated a Hold, with 2025 numbers showing improved EBITDA and a substantial $220 million debt reduction. Read more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results